Skip to main content
SpringerLink
Log in

Other uses of dexrazoxane: savene, the first proven antidote against anthracycline extravasation injuries

  • Published:
Cardiovascular Toxicology Aims and scope Submit manuscript

Abstract

Dexrazoxane has been in clinical use for more than 25 years for prevention of cardiotoxicity in anthracycline based anticancer therapy. However, we discovered another property of the compound, i.e. the ability to prevent the devastating tissue necrosis after accidental extravasation of anthracyclines. The preclinical and clinical studies leading to the clinical implementation of Savene™ (dexrazoxane) as the first and only proven antidote in anthracycline extravasation are described in short.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Sehested, M., Jensen, P. B., Sorensen, B. S., Holm, B., Friche, E., & Dermant, E. J. F. (1993). Antagonistic effect of the cardioprotector (+)-1,2-Bis(3,5-Dioxopiperazinyl-1-yl)propane (ICRF-187) on DNA breaks and cytotoxicity induced by the topoisomerase II directed drugs daunorubicin and etoposide (VP-16). Biochemical Pharmacology, 46, 389–393.

    Article  PubMed  CAS  Google Scholar 

  2. Langer, S. W., Sehested, M., & Jensen, P. B. (2000). Treatment of anthracycline extravasation with dexrazoxane. Clinical Cancer Research, 6, 3680–3686.

    PubMed  CAS  Google Scholar 

  3. Langer, S. W., Sehested, M., & Jensen, P. B. (2001). Dexrazoxane is a potent and specific inhibitor of anthracycline induced subcutaneous lesions in mice. Annual Oncology, 12, 405–410.

    Article  CAS  Google Scholar 

  4. Langer, S.W., Thougaard, A. V., & Sehested. M et al. (2006). Treatment of anthracycline extravasation in mice with dexrazoxane with or without DMSO and hydrocortisone. Cancer Chemotherapy and Pharmacology, 57, 125–128.

    Article  PubMed  CAS  Google Scholar 

  5. Langer, S. W., Sehested, M., & Jensen, P. B. et al. (2000). Dexrazoxane in anthracycline extravasation. Journal of Clinical Oncology, 18, 3064.

    PubMed  CAS  Google Scholar 

  6. Bos, A. M., van der Graaf, W. T., & Willemse, P. H. (2001). A new conservative approach to extravasation of anthracyclines with dimethylsulfoxide and dexrazoxane. Acta Oncology, 40, 541–542.

    Article  CAS  Google Scholar 

  7. Jensen, J. N., Lock-Andersen, J., & Langer, S. W. et al. (2003). Dexrazoxane–a promising antidote in the treatment of accidental extravasation of anthracyclines. Scandinavian Journal of Plastic and Reconstructive Surgery and Hand Surgery, 37, 174–175.

    Article  PubMed  Google Scholar 

  8. El Saghir, N., Otrock, Z., & Mufarrij, A. et al. (2004). Dexrazoxane for anthracycline extravasation and GM-CSF for skin ulceration and wound healing. Lancet Oncology, 5, 320–321.

    Article  PubMed  CAS  Google Scholar 

  9. Mouridsen, H. T., Langer, S.W., & Buter, J. et al. (2006). Treatment of anthracycline extravasation with Savene (dexrazoxane): results from two prospective clinical multicentre studies. Annual Oncology, Dec 21.

  10. Mouridsen, H. T. et al. Treatment of anthracycline extravasation with Savene (dexrazoxane). Results from two prospective clinical multicenter studies. Annals of Oncology. (In press).

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, Diagnostic Centre, National University Hospital, Rigshospitalet 5444, Frederik V’s Vej 11, 2100, Copenhagen, Denmark

    Seppo W. Langer, Peter Buhl Jensen & Maxwell Sehested

Authors
  1. Seppo W. Langer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter Buhl Jensen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Maxwell Sehested
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Maxwell Sehested.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Langer, S.W., Jensen, P.B. & Sehested, M. Other uses of dexrazoxane: savene, the first proven antidote against anthracycline extravasation injuries. Cardiovasc Toxicol 7, 151–153 (2007). https://doi.org/10.1007/s12012-007-0021-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12012-007-0021-5

Keywords

Search

Navigation